BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12673563)

  • 1. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
    Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
    Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of beta-catenin is a late event in the pathogenesis of nephroblastomas and rarely correlated with genetic changes of the APC gene.
    Grill C; Sunitsch S; Hatz M; Hauser-Kronberger C; Leuschner I; Hoefler G; Guertl B
    Pathology; 2011 Dec; 43(7):702-6. PubMed ID: 22081130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
    Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
    Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic clonality is a feature unifying nephroblastomas regardless of the variety of morphological subtypes.
    Guertl B; Leuschner I; Harms D; Hoefler G
    Virchows Arch; 2006 Aug; 449(2):171-4. PubMed ID: 16715229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.
    Huff V; Reeve AE; Leppert M; Strong LC; Douglass EC; Geiser CF; Li FP; Meadows A; Callen DF; Lenoir G
    Cancer Res; 1992 Nov; 52(21):6117-20. PubMed ID: 1356625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
    Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
    Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions.
    Karnik P; Chen P; Paris M; Yeger H; Williams BR
    Oncogene; 1998 Jul; 17(2):237-40. PubMed ID: 9674708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
    Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
    J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
    Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
    Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of MIB and BCL-2 in patients with nephrogenic rests with and without associated Wilms' tumors.
    Wünsch L; Flemming P; Glüer S
    Eur J Pediatr Surg; 2001 Apr; 11(2):105-9. PubMed ID: 11371029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
    J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.